Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
They are considered prescription-only medicines or declared substances, by way of the Medicines, Poisons and Therapeutic Goods Act 2008 (ACT)
Key Research Features Four-component co-lyophilized research blend four simultaneous mechanistic pathways GHK-Cu: ECM remodeling, collagen synthesis, copper coordination chemistry BPC-157: VEGFR2/Akt-eNOS angiogenic signaling, NO pathway modulation TB-500: actin sequestration, cytoskeletal dynamics, cell migration KPV: NF-B nuclear translocation inhibition via importin-3 competitive binding Fixed 50:10:10:10mg ratio single co-lyophilization run ensures uniform aliquot composition 99% RP-HPLC-verified purity per component Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, KLOW should be: Stored at 28C (lyophilized) or 20C (reconstituted) Reconstituted in bacteriostatic water or sterile PBS, added slowly with gentle swirling do not vortex Aliquoted immediately into single-use working volumes after reconstitution Protected from light and moisture Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information All four components evaluated in preclinical toxicology and regenerative biology research models All four components designated FDA Category 2 bulk substances (503A/503B compounding lists, September 2023) Compounding by licensed 503A/503B pharmacies for human use prohibited for all four components Not evaluated by the FDA for safety or efficacy in any therapeutic application Supplied strictly as a Research Use Only (RUO) material PPE required: gloves, lab coat, protective eyewear
It decides how much you actually get out of a session you paid for
Gastrointestinal (GI) side effects are common in people with diabetes treated both with metformin and with GLP-1 receptor agonists (GLP-1 RAs), and they are the commonest reason for discontinuation of these drugs in clinical practice
